BACKGROUND: ErbB receptors and their cognate ligands are implicated in cancer progression. Their expression in gastrointestinal cancer, however, has not been systemically studied. MATERIALS AND METHODS: The expression of four ErbB receptors and a panel of ErbB ligands were determined by reverse transcription-PCR in two gastric (TMK1, MKN-45) and two colon (SW1116, HT-29) cancer cell lines. Cell proliferation was measured by MTT assay while gene knockdown was achieved by RNA interference. RESULTS: ErbB1, ErbB2 and ErbB3 receptors and five known or putative ErbB ligands, namely, epiregulin, epidermal growth factor (EGF), heparin-binding EGF, transforming growth factor alpha (TGFalpha) and neuroglycan-C were expressed in all four cell lines. Knockdown of neuroglycan-C, however, did not affect cell proliferation. CONCLUSION: This study profiles the expression of ErbB receptors and their cognate ligands in gastric and colon cancer cells. These findings might lay the basis for the development of ErbB pathway-directed therapeutics for gastrointestinal cancer.
BACKGROUND:ErbB receptors and their cognate ligands are implicated in cancer progression. Their expression in gastrointestinal cancer, however, has not been systemically studied. MATERIALS AND METHODS: The expression of four ErbB receptors and a panel of ErbB ligands were determined by reverse transcription-PCR in two gastric (TMK1, MKN-45) and two colon (SW1116, HT-29) cancer cell lines. Cell proliferation was measured by MTT assay while gene knockdown was achieved by RNA interference. RESULTS:ErbB1, ErbB2 and ErbB3 receptors and five known or putative ErbB ligands, namely, epiregulin, epidermal growth factor (EGF), heparin-binding EGF, transforming growth factor alpha (TGFalpha) and neuroglycan-C were expressed in all four cell lines. Knockdown of neuroglycan-C, however, did not affect cell proliferation. CONCLUSION: This study profiles the expression of ErbB receptors and their cognate ligands in gastric and colon cancer cells. These findings might lay the basis for the development of ErbB pathway-directed therapeutics for gastrointestinal cancer.
Authors: Valda C Hilliard; Mark R Frey; Peter J Dempsey; Richard M Peek; D Brent Polk Journal: Am J Physiol Gastrointest Liver Physiol Date: 2011-05-26 Impact factor: 4.052
Authors: Julia Fangfei Yan; Hoguen Kim; Seul-Ki Jeong; Hyoung-Joo Lee; Manveen K Sethi; Ling Y Lee; Ronald C Beavis; Hogune Im; Michael P Snyder; Matan Hofree; Trey Ideker; Shiaw-Lin Wu; Young-Ki Paik; Susan Fanayan; William S Hancock Journal: J Proteome Res Date: 2015-10-20 Impact factor: 4.466